Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-MTAB-6763

ABSTRACT: Effect of MHC II expression in pro-B cells: F6 leukaemic cell line

PROVIDER: E-MTAB-6763 | ExpressionAtlas | 2018-09-17

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-MTAB-6763-analysis-methods.tsv	Tabular
	E-MTAB-6763-analytics.tsv	Tabular
	E-MTAB-6763-atlasExperimentSummary.Rdata	Rdata
	E-MTAB-6763-configuration.xml	Xml
	E-MTAB-6763-g2_g1-mvaPlot.png	Other

Items per page:

1 - 5 of 21

Similar Datasets

Effect of MHC II expression in pro-B cells: F6 leukaemic cell line

Project description:Effect of MHC II expression in pro-B cells: F6 leukaemic cell line

| PRJEB26756 | ENA

Human melanoma cell lines secretome analysis

Project description:The imbalance of cellular homeostasis during oncogenesis together with the high heterogeneity of tumor-associated stromal cells have a marked effect on the repertoire of the proteins secreted by malignant cells (the secretome). Hence, the study of tumoral secretomes provides insights for understanding the cross-talk between cells within the tumor microenvironment as well as the key effectors for the establishment of the pre-metastatic niche in distant tumor sites. In this context, we performed a proteomic analysis of the secretomes derived from four cell lines: (i) a paired set of fibroblasts - Hs 895. T, a cell line obtained from a lung node metastatic site from a patient who had melanoma and Hs 895.Sk, a skin fibroblast cell line (derived from the same patient); (ii) two malignant metastatic melanoma cell lines - A375, a malignant melanoma cell line from primary source and SH-4, a cell line derived from pleural effusion of a patient with metastatic melanoma. Clustering of expression profiles together with functional enrichment revealed patterns that mirrored each cell type (skin fibroblasts, cancer-associated fibroblasts and metastatic cells). These patterns might be the result of cell-specific protein expression programs and may serve as basis for further proteomic analysis of melanoma cell lines secretomes.

2018-01-02 | PXD007265 | Pride

Homo sapiens

Project description:miR-135b expression effect on myxoid liposarcoma cell line

| PRJNA296774 | ENA

Effect of insulin on 3T3L1 cell line gene expression

Project description:Effect of insulin on 3T3L1 cell line gene expression

| PRJNA606168 | ENA

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Project description:This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies. In a donor stem cell transplant, the donated stem cells may replace the patient’s immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor’s T cells (donor lymphocyte infusion) after the transplant may help increase this effect.

| 2143763 | ecrin-mdr-crc

iAR22_SARS-CoV-2_scH1299 - cell-type specific constraint-based metabolic models of human H1299 cells with SARS-CoV-2 infection

Project description:A collection of cell-type specific constraint-based metabolic models of human H1299 cells (human non-small cell lung carcinoma cell line) infected with SARS-CoV-2 based that were generated based on gene-expression data.

2025-04-07 | MODEL2311070004 | BioModels

iAR22_SARS-CoV-2_Calu3 - A collection of cell-type specific constraint-based metabolic models of human Calu-3 cells infected with SARS-CoV-2

Project description:A collection of cell-type specific constraint-based metabolic models of Calu-3 cells (a human lung epithelial cancer cell line) infected with SARS-CoV-2 based that were generated based on gene-expression data.

2025-04-14 | MODEL2311070005 | BioModels

Selective inhibition of CDK9 in triple negative breast cancer

Project description:Targeted treatment for triple-negative breast cancer (TNBC) remains an elusive clinical challenge. Cyclin-dependent kinase 9 (CDK9) is a transcriptional regulator shown to promote growth of multiple cancers, including TNBC, and represents a potential new therapeutic target. CDK9 increases RNA Polymerase II (Pol II) activity, which facilitates sustained expression of short-lived oncogenic and anti-apoptotic proteins. However, pre-clinical evaluation of CDK9 as a therapeutic target has been hampered by the poor selectivity of existing CDK9 inhibitors (CDK9i). Here, we report a novel CDK9i; D11-8, which exhibits high potency against CDK9 (Ki = 8 nM) and displays remarkable selectivity over other CDKs and human kinases. D11-8 inhibited TNBC cell line proliferation,, induced G2/M cell cycle arrest, and increased apoptosis. Mechanistically, D11-8 inhibited CDK9; reducing Pol II phosphorylation, down-regulating expression of proto-oncogene MYC and anti-apoptotic marker MCL1, and dramatically inducing Pol II promoter-proximal pausing at MYC, G2/M checkpoint, and E2F2 target genes. D11-8 was further validated for TNBC in vivo, and inhibited TNBC cell line tumour growth without toxicity. To further elucidate the cancer cell specificity of D11-8, normal breast tissue was collected from women undergoing reduction mammoplasty surgery and treated with D11-8 ex vivo as patient-derived explants. High doses of D11-8 (2.7 µM) had no effect on the proliferative capacity of normal breast epithelial cells (Ki67 positivity), and tissues appeared histologically normal. Collectively, these data demonstrate that D11-8 effectively inhibits CDK9 in TNBC cell lines, resulting in growth inhibition without short-term toxicity.

2023-11-25 | GSE184335 | GEO

Unraveling the CDK9/PP2A/ERK network in transcriptional pause release and complement activation in KRAS-mutant cancers

Project description:A time-course RNA-seq experiment testing the effect of drug treatment using selective CDK9 inhibitor AZD4573. The experiment was done using a pancreatic cancer cell line HPAF-II carrying KRAS G12D mutation.

2024-08-31 | GSE270409 | GEO

Transcription profiling of human HepG2 cell line exposed to aminocetophen - LGC_ACAP_WITHIN_RIN_DD4_Tox

Project description:To: (i)Determine the effect of sample RNA integrity as determined by RIN on an expression profile generated in a HepG2 cell line in response to challenge by a specific pharmaceutically active compound (acetaminophen).<br><br>To:(ii)Determine the within RIN variability on an expression profile generated in a HepG2 cell line in response to challenge by a specific pharmaceutically active compound (acetaminophen).

2010-09-03 | E-MEXP-2346 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data